• EGCG Analogs for Extracellular and Intracellular S. aureus

  2026-08-14

  Grosso and colleagues chemically modified (-)-Epigallocatechin gallate (EGCG) to address its poor stability and membrane permeability while retaining or improving antistaphylococcal activity. The lead analogs MCC-1 and MCC-2 showed enhanced activity against extracellular Staphylococcus aureus, restored β-lactam susceptibility in MRSA, and improved macrophage- and antibiotic-mediated clearance of intracellular bacteria.

• BFH772 (VEGFR2 inhibitor): Practical Guide

  2026-08-14

  BFH772 is a selective VEGFR2 inhibitor for experiments that require pathway-focused modulation of angiogenesis, including tumor angiogenesis research. Its water insolubility and organic-solvent dependence make it unsuitable for workflows requiring aqueous formulations or broad-spectrum kinase inhibition.

• Omeprazole A2845: Research Workflow Guide

  2026-08-13

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for gastric acid secretion research, with dossier-reported activity benchmarks and DMSO solubility guidance. It is intended for controlled laboratory studies, including antiulcer activity studies and peptic ulcer disease models, and must not be used for diagnostic, clinical, or medical purposes.

• (R)-MG132 for Proteasome Assay Validation

  2026-08-13

  (R)-MG132 is a low-activity MG-132 enantiomer designed to separate proteasome-dependent effects from solvent, peptide-aldehyde, and cell-stress artifacts. This workflow shows how to deploy it in biochemical assays, cell-based studies, and mechanistic experiments related to ubiquitin-dependent protein regulation.

• BIBR 1532: Telomerase Inhibition Workflows

  2026-08-12

  BIBR 1532 is a selective, non-nucleosidic telomerase inhibitor for linking hTERT suppression with cancer cell proliferation inhibition, telomere attrition, and apoptosis. This workflow-focused guide shows how to distinguish acute enzyme inhibition from delayed telomere-dependent effects and how to design combination studies responsibly.

• DOT1L Blockade in Renal Fibrosis: Study Insights

  2026-08-12

  The reference study identifies DOT1L-dependent H3K79 methylation as a regulator of renal fibroblast activation, epithelial–mesenchymal transition, and injury-associated signaling in experimental renal fibrosis. Its combination of pharmacologic inhibition, DOT1L silencing, cell-based models, and unilateral ureteral obstruction provides a mechanistic framework for evaluating DOT1L inhibition beyond oncology.

• Pitavastatin (NK-104): In Vitro QC Guide

  2026-08-11

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for controlled studies of cholesterol biosynthesis and related cellular responses. It is suited to in vitro biochemical and cell-based workflows, but the supplied information does not validate direct clinical use, animal dosing, or substitution for a matched research protocol.

• Cyclo (-RGDfC) for Integrin-Targeted Cell Assays

  2026-08-10

  Cyclo (-RGDfC) turns αvβ3 integrin biology into practical adhesion, migration, viability, and targeting assays. This workflow combines receptor validation, matched fibroblast controls, fresh DMSO handling, and orthogonal readouts to distinguish targeting from nonspecific toxicity.

• Hexetidine Mouthrinse: In Vitro and In Vivo Evidence

  2026-08-09

  Roberts and Addy compared hexetidine with chlorhexidine, alexidine, and cetyl pyridinium chloride using both tube-dilution assays and salivary bacterial measurements. The study shows why MIC alone is insufficient for predicting oral performance: hexetidine had the highest MIC values, yet retained measurable salivary antibacterial activity and was relatively resistant to matrix-related loss of activity.

• SW033291: A Translational Lever for Regeneration

  2026-08-08

  SW033291 offers a mechanistically grounded way to study 15-PGDH inhibition, prostaglandin E2 elevation, hematopoietic recovery, and tissue regeneration. New muscle-repair evidence expands the translational conversation while underscoring the need for model-specific validation.

• Temporal Transcriptomics Guides Anti-EBOV Therapies

  2026-08-07

  This preprint combines time-series transcriptomics, co-expression analysis, causal inference, protein-interaction data, and functional screening to identify host programs that change during Ebola virus infection. The work prioritizes RELB, LDLR, and MYC as host factors and identifies Sorafenib and Thioguanine as candidate inhibitors, while highlighting the need for mechanistic and translational validation.

• Nintedanib (BIBF 1120): Precision Targeting in ATRX-Deficien

  2026-08-07

  Explore how Nintedanib (BIBF 1120) advances precision oncology by selectively targeting angiogenesis in ATRX-deficient tumors. This article provides deep mechanistic analysis and actionable guidance for translational cancer research.

• Ruthenium Red: A Potent Ca2+ Transport Inhibitor for Researc

  2026-08-06

  Ruthenium Red is a high-affinity Ca2+ transport inhibitor essential for dissecting calcium signaling and mechanotransduction pathways. It blocks Ca2+ uptake across mitochondrial and sarcoplasmic membranes, enabling reproducible studies of autophagy and neurogenic inflammation. APExBIO’s Ruthenium Red is benchmarked in cytoskeleton-dependent autophagy models and is recommended for advanced calcium signaling research.

• Annexin V, Human Recombinant: Structural Precision for Apopt

  2026-08-06

  Explore how Annexin V, a key phosphatidylserine binding protein, advances apoptosis assay reliability through recombinant technology. This article offers critical insights beyond standard protocols, revealing how structural purity and methodological nuances impact cell death research outcomes.

• Trilaurin (Glycerol Tridodecanoate): Applied Workflows & Opt

  2026-08-05

  Trilaurin (Glycerol Tridodecanoate) is a uniquely versatile lipid excipient, excelling as a biocatalytic substrate and as a critical enabler of advanced oral peptide/protein drug delivery. This article delivers evidence-based, protocol-driven guidance to maximize its impact in enzymatic synthesis and pharmaceutical formulation.

452 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page